Risk of occult hepatitis B virus infection reactivation in patients with solid tumours undergoing chemotherapy

Digestive and Liver Disease

Volumn 45, Issue 8, 2013, Pages 683-686

  Saitta, Carlo ^a   Musolino, Cristina ^a   Marabello, Grazia ^a   Martino, Daniela ^a   Leonardi, Maria Silvana ^a   Pollicino, Teresa ^a   Altavilla, Giuseppe ^a   Raimondo, Giovanni ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Chemotherapy; HBV reactivation; Occult HBV infection; Solid cancer

Indexed keywords

AMINOTRANSFERASE; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; MEMBRANE ANTIGEN; METHOTREXATE; PACLITAXEL; PEMETREXED; TRASTUZUMAB; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS DNA;

ADULT; ARTICLE; BIOCHEMISTRY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; COLON CANCER; FEMALE; GALLBLADDER CANCER; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER DISEASE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PANCREAS CANCER; PHARYNX CANCER; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SEROLOGY; SOLID TUMOR; TESTIS CANCER; VIRUS REACTIVATION;

CHEMOTHERAPY; HBV REACTIVATION; OCCULT HBV INFECTION; SOLID CANCER;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG THERAPY; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SAMPLING STUDIES; VIRAL LOAD;

EID: 84881553525     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.01.022     Document Type: Article

References (21)

1. Lee W.M. Hepatitis B virus infection. New England Journal of Medicine 1997, 337:1733-1745.
2. Ganem D., Prince A.M. Hepatitis B virus infection - natural history and clinical consequences. New England Journal of Medicine 2004, 350:1118-1129.
3. Yeo W., Johnson P.J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006, 43:209-220.
4. Lalazar G., Rund D., Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. British Journal of Haematology 2007, 136:699-712.
5. Katz L.H., Fraser A., Gafter-Gvili A., et al. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. Journal of Viral Hepatitis 2008, 15:89-102.
6. Hui C.K., Cheung W.W., Zhang H.Y., et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006, 131:59-68.
7. Raimondo G., Allain J.P., Brunetto M.R., et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. Journal of Hepatology 2008, 49:652-657.
8. Hui C.K., Cheung W.W., Leung K.W., et al. Outcome and immune reconstitution of HBV-specific immunity in patients with reactivation of occult HBV infection after alemtuzumab-containing chemotherapy regimen. Hepatology 2008, 48:1-10.
9. Raimondo G., Pollicino T., Cacciola I., et al. Occult hepatitis B virus infection. Journal of Hepatology 2007, 46:160-170.
10. Raimondo G., Caccamo G., Filomia R., et al. Occult HBV infection. Seminars in Immunopathology 2013, 35:39-52.
11. Marzano A., Angelucci E., Andreone P., et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Digestive and Liver Disease 2007, 39:397-408.
12. Pei S.N., Chen C.H., Lee C.M., et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Annals of Hematology 2010, 89:255-262.
13. Cacciola I., Pollicino T., Squadrito G., et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. New England Journal of Medicine 1999, 341:22-26.
14. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. Journal of Hepatology 2012, 57:167-185.
15. Koo Y.X., Tay M., Teh Y.E., et al. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Annals of Hematology 2011, 90:1219-1223.
16. Marcucci F., Mele A., Spada E., et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica 2006, 91:554-557.
17. Kannangai R., Vivekanandan P., Netski D., et al. Liver enzyme flares and occult hepatitis B in persons with chronic hepatitis C infection. Journal of Clinical Virology 2007, 39:101-105.
18. Torbenson M., Thomas D.L. Occult hepatitis B. Lancet Infectious Diseases 2002, 2:479-486.
19. Raimondo G., Navarra G., Mondello S., et al. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. Journal of Hepatology 2008, 48:743-746.
20. Onozawa M., Hashino S., Izumiyama K., et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005, 79:616-619.
21. Vigano M., Vener C., Lampertico P., et al. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplantation 2011, 46:125-131.